PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.

Abstract Through analysis and summarization of clinicopathological features, immunohistochemical expression, pathological diagnostic criteria, prognostic and other factors in patients suffering from bladder neuroendocrine carcinoma (BNEC), a better understanding of BNEC could be achieved to provide solid evidence for clinicopathology and prognosis.
PMID
Related Publications

Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases.

Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases.

Analysis of clinicopathological features of intestinal neuroendocrine neoplasms.

Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution.

Neuroendocrine carcinoma of the urinary bladder:clinicopathologic features analysis of 17 cases.

Authors

Mayor MeshTerms
Keywords

Bladder

NEC

immunohistochemistry

pathological features

Journal Title anticancer research
Publication Year Start



 

PMID- 28739749
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of
      Bladder Neuroendocrine Carcinoma.
PG  - 4529-4537
AB  - AIM: Through analysis and summarization of clinicopathological features,
      immunohistochemical expression, pathological diagnostic criteria, prognostic and 
      other factors in patients suffering from bladder neuroendocrine carcinoma (BNEC),
      a better understanding of BNEC could be achieved to provide solid evidence for
      clinicopathology and prognosis. MATERIALS AND METHODS: The clinicopathological
      data of 39 cases of BNEC with up to 5-year follow-up data (median follow-up=650
      days) were analyzed retrospectively based on immunohistochemical staining.
      Survival analyses were carried out using the Kaplan-Meier method and tested with 
      the log-rank method. Multivariate Cox regression analysis was adopted to screen
      independent risk factors affecting patients' survival. In these 39 cases of BNEC,
      there were 26 cases of male patients, 13 female, with the proportion of male to
      female being 2:1. The ages of onset ranged from 44 to 86, with the median age
      being 62 and the average age 61.97 years, respectively. Histologically, referring
      to the WHO standard of neuroendocrine lung tumor classification, there were 7
      cases of typical carcinoid tumors, 8 atypical carcinoid, 12 small-cell carcinomas
      and 12 large-cell carcinomas. In these cases there were 11 cases of featured
      urothelium carcinomas and 9 cases of adenocarcinomas. RESULTS:
      Immunohistochemical staining showed that, in these 39 cases of BNEC, the positive
      expression for the neuroendocrinic markers, including neural cell adhesion
      molecule 56 (CD56), synaptophysin (Syn), chromogranin A (CgA), neuron-specific
      enolase (NSE), thyroid transcription factor-1 (TTF-1), cytokeratin (CK) and
      cytokeratin 7 (CK7), accounted for 39/39, 27/39, 18/39, 39/39, 19/39, 10/39 and
      8/39, respectively. In contrast, cytokeratin 20 (CK20), protein 63 (P63), human
      melanoma black 45 (HMB45), S-lfln protein 100 (S-100) and leukocyte common
      antigen (LCA) were all negatively expressed. During the follow-up period, 12
      patients died. The 1-, 3- and 5-year overall survival (OS) rates were 76.92%,
      74.36% and 69.23%. CONCLUSION: BNEC is one of the most malignant tumors with
      severe invasiveness and poor prognosis. Immunohistochemistry revealed that CD56, 
      Syn, CgA, NSE, TTF-1, CK, CK7, CK20, P63, HMB45, S-100 protein and LCA immune
      markers play important roles in diagnosis and differentiation. Many factors,
      including the patient's age, size and shape of the tumor, operative method,
      perineuronal invasion, vascular invasion, distant organ metastasis and
      pathological type, show great difference in influencing OS time of patients,
      among which the size of the tumor, no invasion, vascular invasion and distant
      organ metastasis are independent risk factors affecting prognosis (survival
      time). Radical cystectomy is the prior alternative to treat this tumor.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Zhou, Hui-Hui
AU  - Zhou HH
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China.
FAU - Liu, Li-Yan
AU  - Liu LY
AD  - Department of Medicine, The fifth People's Hospital of Jinan, Jinan, P.R. China.
FAU - Yu, Guo-Hua
AU  - Yu GH
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China.
FAU - Qu, Gui-Mei
AU  - Qu GM
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China.
FAU - Gong, Pei-You
AU  - Gong PY
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China.
FAU - Yu, Xiao
AU  - Yu X
AD  - Department of Medicine Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China [email protected] [email protected]
FAU - Yang, Ping
AU  - Yang P
AD  - Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R.
      China [email protected] [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers
MH  - Biopsy
MH  - Carcinoma, Neuroendocrine/metabolism/*mortality/*pathology/therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phenotype
MH  - Prognosis
MH  - Risk Factors
MH  - Sex Factors
MH  - Tumor Burden
MH  - Urinary Bladder Neoplasms/metabolism/*mortality/*pathology/therapy
OTO - NOTNLM
OT  - Bladder
OT  - NEC
OT  - immunohistochemistry
OT  - pathological features
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/02 [received]
PHST- 2017/05/25 [revised]
PHST- 2017/05/26 [accepted]
AID - 37/8/4529 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4529-4537.